A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy

Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.

Inclusion Criteria:

• Metastatic pancreatic cancer with metastases amenable to biopsy
• Willingness to provide tissue and blood samples for research purposes
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

Exclusion Criteria:

• History of islet cell, acinar cell, or cystadenocarcinomas
• Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)
• Radiation therapy, immunotherapy or biologic therapy <28 days prior to study entry